Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
Where does AN say he is delighted with $1.2M? he doesn't. The RNS says the company is delighted to receive an additional contract, return business.
Learn to read phuckwhit
or are you just annoyed you didn't get back in before the rise
Rivals are focusing on developing tests that could be used to diagnose patients with early-stage cancers, before they begin to experience symptoms. This could be revolutionary but is fraught with risk because the tests must be very accurate to avoid false positives.
In contrast, Angle is focusing on tracking already diagnosed cancers to enable more personalised treatment and is selling a testing product to labs rather than offering a service.
As demand soars, Angle plans to expand its workforce by 50 per cent this year and to double the size of its headquarters.
But Newland said there had been far more appetite for the test in the US than from the UK’s NHS, even though it has the EU CE mark.
The company has worked with top UK cancer research centres such as Barts Cancer Institute but would like to roll it out more extensively across the health service, where it has been “very, very difficult to gain traction�.
“Unfortunately, we failed miserably. We tried. But we’re finding all the traction is coming on the United States side, which is very disappointing,� he said. “We can even provide this test at relatively low cost . . . but it’s just impossible to find anybody who’s able to make a decision.�